Drug Profile
Etirinotecan pegol - Nektar Therapeutics
Alternative Names: Irinotecan - Nektar Therapeutics; NKTR-102; ONZEALD; PEG-Irinotecan; Pegylated irinotecan - Nektar TherapeuticsLatest Information Update: 17 Dec 2021
Price :
$50
*
At a glance
- Originator Nektar Therapeutics
- Developer Clovis Oncology [CEASED]; Mayo Clinic; Nektar Therapeutics; Roswell Park Cancer Institute; Stanford University School of Medicine; University of Pennsylvania Cancer Center
- Class Alkaloids; Antineoplastics; Camptothecins; Heterocyclic compounds with 4 or more rings; Indolizines; Piperidines; Polyethylene glycols; Quinolines
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Breast cancer; Cervical cancer; Colorectal cancer; Solid tumours
- Discontinued Glioma; Non-small cell lung cancer; Ovarian cancer; Small cell lung cancer
Most Recent Events
- 01 Jun 2021 Discontinued - Phase-II for Colorectal cancer (Metastatic disease, Monotherapy, Second-line therapy or greater) in Belgium, Germany, United Kingdom, Spain, India, USA, before June 2021 (IV)
- 01 Jun 2021 Discontinued - Phase-II for Glioma (Monotherapy, Second-line therapy or greater) in USA before June 2021 (IV)
- 01 Jun 2021 Discontinued - Phase-II for Non-small cell lung cancer (Metastatic disease, Second-line therapy or greater) in USA before June 2021